PTPN11 and cancer: By fusing VHL with the VHH domain nanobodies recognizing the inflammasomal protein ASC [48], or by fusing VHL to either of the two monobodies that specifically bind the tyrosine phosphatase SHP2 [42], we showed robust degradation of endogenous ASC and SHP2 proteins, respectively, in a whole host of human cancer cell lines [19].